GREY MICHAEL G

MIRM director Michael G Grey sells all 50,000 shares at $78.00; complete exit from $3.9M position near 52-week high

Michael G Grey, a director, executed a complete exit from Mirum Pharmaceuticals by selling 50,000 shares at $78.00 on 2025-12-19 for $3,900,000.00, reducing his holdings from 50,000 shares to 0. The sale occurred near the 52-week high (current price $80.05 is -1.3% from the $81.07 peak), suggesting the director sold into strength during a period of recent momentum (+12.8% over 30 days). Notably, this represents the third sale by Grey at MIRM within recent weeks, following sales on 2025-12-01 and 2025-11-21. The company's recent fundamentals show strong revenue growth of +80.8% annually and latest quarter revenue of $133,010,000.00, though it remains unprofitable on a full-year basis, which may be relevant context for a director's decision to liquidate an entire position.

Director Grey Michael G sells entire 50,000-share MIRM stake for $3.7M at $74.00, exiting to zero holdings

Director Grey Michael G completely liquidated his 50,000-share position in Mirum Pharmaceuticals for $3,700,000.00 at $74.00 on 2025-12-01, reducing his holdings from 50,000 shares to 0 shares (-100.0%). This full exit occurred within days of a prior same-ticker sell on 2025-11-21 of 30,000 shares, forming a rapid two-step liquidation pattern totaling 80,000 shares in 10 days. The stock has declined 3.8% over the past 30 days and 6.3% over 90 days from the transaction date, trading at $69.88 (current price) versus the $74.00 sale price. While the company posted strong annual revenue growth of +80.8% and quarterly revenue of $133,010,000.00, it remains unprofitable on a full-year basis with net income of $2,905,000.00 in the latest quarter, leaving investors to assess whether the director's complete exit reflects confidence-dampening fundamentals or personal capital reallocation.

Director Grey sold 50,000 shares ($3.5M) at $70.00, liquidating entire position, as firm swings to profitability.

GREY MICHAEL G, a Director, sold 50,000 shares (50.0K shares) on 2025-11-21 at $70.00 per share for $3,500,000.00 ($3.5M), reducing his holdings from 50,000 shares to 0 shares post-transaction. The company reported recent profitability with net income of $2,905,000.00 ($2.9M) in the latest quarter, while annual revenue growth reached +80.8%, yet full-year net income was negative. The stock is trading at $71.76 (current), near its 52-week high range of $38.39–$77.69 with a -7.6% gap from the 52-week high. The complete elimination of the director's holdings at valuations close to all-time highs, coinciding with the firm's transition toward profitability, represents a material change in insider commitment to the equity and warrants monitoring of insider confidence in forward valuation.